Table 2.
Baseline characteristics for the HbA1c and weight cohorts with data at 6 and 12 months and at least two prescriptions for baseline GLP-1 RA
| Follow-up | 6 months | 12 months | ||
|---|---|---|---|---|
| HbA1c cohort n = 545 | Weight cohort n = 692 | HbA1c cohort n = 291 | Weight cohort n = 415 | |
| Age, years | 58.7 (10.3) | 58.5 (10.5) | 58.6 (9.5) | 59.2 (9.6) |
| Sex, men/women, % | 42.6/57.4 | 40.9/59.1 | 41.9/58.1 | 40.7/59.3 |
| Weight, kg | 106.6 (26.2) | 106.7 (26.1) | 103.7 (25.3) | 104.9 (25.9) |
| BMI, kg/m2 | 36.8 (8.3) | 36.8 (8.3) | 35.7 (7.8) | 36.4 (8.4) |
| HbA1c, % | 8.0 (1.6) | 8.1 (1.7) | 7.9 (1.7) | 8.0 (1.7) |
| Charlson–Deyo risk index score [20, 21] | 2.5 (1.9) | 2.6 (2.1) | 2.3 (1.8) | 2.6 (2.0) |
| CVD (12 months before/any time before index date), % | 16.1/29.4 | 19.2/33.1 | 13.7/23.7 | 18.8/31.6 |
| Baseline GLP-1 RA treatment, n (%) | ||||
| Liraglutide | 249 (45.7) | 341 (49.3) | 120 (41.2) | 198 (47.7) |
| Dulaglutide | 205 (37.6) | 251 (36.3) | 118 (40.5) | 139 (33.5) |
| Exenatide once weekly | 110 (20.2) | 119 (17.2) | 72 (24.7) | 88 (21.2) |
| Albiglutide | 9 (1.7) | 13 (1.9) | 7 (2.4) | 13 (3.1) |
| Lixisenatide | 11 (2.0) | 17 (2.5) | 7 (2.4) | 8 (1.9) |
| Exenatide twice daily | 3 (0.6) | 6 (0.9) | 1 (0.3) | 5 (1.2) |
| Exenatide, frequency not specified | 14 (2.6) | 19 (2.7) | 5 (1.7) | 11 (2.7) |
| Starting dose of injectable semaglutide, n (%) | ||||
| 1 mg | 82 (16.5) | 95 (15.0) | 43 (16.2) | 60 (15.8) |
| 0.25 mg/0.5 mg | 415 (83.5) | 539 (85.0) | 223 (83.8) | 320 (84.2) |
| Baseline medication, n (%) | ||||
| Biguanides | 326 (59.8) | 384 (55.5) | 177 (60.8) | 235 (56.6) |
| Sulphonylureas | 117 (21.5) | 139 (20.1) | 55 (18.9) | 87 (21.0) |
| Thiazolidinediones | 83 (15.2) | 83 (12.0) | 41 (14.1) | 55 (13.3) |
| DPP-4i | 67 (12.3) | 78 (11.3) | 39 (13.4) | 46 (11.1) |
| SGLT-2i | 208 (38.2) | 211 (30.5) | 107 (36.8) | 129 (31.1) |
| Combinations | 90 (16.5) | 95 (13.7) | 46 (15.8) | 54 (13.0) |
| Long-acting insulin | 208 (38.2) | 271 (39.2) | 110 (37.8) | 153 (36.9) |
| Fast-acting insulin | 75 (13.8) | 114 (16.5) | 36 (12.4) | 64 (15.4) |
| Any type of insulin | 224 (41.1) | 300 (43.4) | 118 (40.5) | 174 (41.9) |
BMI body mass index, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated haemoglobin, SD standard deviation, SGLT-2i sodium-glucose co-transporter-2 inhibitor. Data are means (SD) except where otherwise stated. The Charlson–Deyo risk index is used to predict 10-year survival in patients with multiple comorbidities. CVD included coronary heart disease, cerebrovascular disease, peripheral vascular disease and heart failure